Suven Life Sciences secures product patents in Australia, Eurasia, Europe

09 May 2018 Evaluate

Suven Life Sciences has secured one product patent from Australia, one product patent from Eurasia and one product patent from Europe corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.

The granted claims of the patents include the class of selective 5-HT4 compound and is being developed as therapeutic agents for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

164.90 -0.25 (-0.15%)
02-Jan-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1730.30
Dr. Reddys Lab 1255.45
Cipla 1511.70
Zydus Lifesciences 917.00
Lupin 2108.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×